1-isobutyrylamino-1,2,3,4-tetrahydronaphthalene | 923138-29-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-isobutyrylamino-1,2,3,4-tetrahydronaphthalene
• 英文别名: 2-methyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)propanamide
• CAS: 923138-29-8
• 化学式: C₁₄H₁₉NO
• mdl: MFCD04549555
• 分子量: 217.311
• InChiKey: INUZQBFAWXFNGW-UHFFFAOYSA-N

物化性质

• 沸点：
  401.511±25.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.043±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] TETRALINE SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS<br/>[FR] DÉRIVÉS DE SULFONAMIDE DE TÉTRALINE POUR L'UTILISATION DANS LE TRAITEMENT DE TROUBLES DE PROLIFÉRATION
  申请人：UNIV NOTRE DAME DE LA PAIX

  公开号：WO2012175654A1

  公开（公告）日：2012-12-27

  Tetraline sulfonamides derivatives highly specific towards CA IX and/or CA XII human carbonic anhydrase for targeting solid tumors.

  四环磺胺衍生物对人类碳酸酐酶CA IX和/或CA XII具有高度特异性，用于靶向固体肿瘤。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：Naraian S. Ashok

  公开号：US20070078146A1

  公开（公告）日：2007-04-05

  A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义，其中R1、R2、R3和R4如规范中所述。
• ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I
  申请人：Ogawa Tomoyuki

  公开号：US20090131491A1

  公开（公告）日：2009-05-21

  Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is a group of the formula: —C(═O)NR 4 R 5 , (wherein R 4 and R 5 are each independently, hydrogen, optionally substituted alkyl or the like) or a group of the formula: —NR 6 C(═O)R 7 , (wherein R 6 and R 7 are each independently, hydrogen, optionally substituted alkyl or the like), X and Y are each independently —O— or the like, Z is a bond or the like, R 2 is optionally substituted alkyl, optionally substituted alkenyl or the like, R 3 is optionally substituted alkyl, optionally substituted alkenyl or the like.
• HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
  申请人：Ogawa Tomoyuki

  公开号：US20100197662A1

  公开（公告）日：2010-08-05

  Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted cycloalkyl, optionally substituted cycloalkenyl or the like, One of R 2 and R 3 is a group of the formula: —C(═O)—Y—R 4 , wherein Y is —NR 9 — or the like, R 4 is optionally substituted cycloalkyl or the like, R 9 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, The other is a group of the formula: —V—R 5 , wherein V is a bond, —O— or the like, R 6 is hydrogen or optionally substituted alkyl, R 5 is hydrogen, optionally substituted alkyl or the like, X is a bond, —S—, —SO— or the like, U is a bond or optionally substituted alkylene, R 7 is hydrogen or optionally substituted alkyl, Z is —S—, —O— or —NR 8 —, R 8 is hydrogen, optionally substituted alkyl or the like.
• INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20210387986A1

  公开（公告）日：2021-12-16

  Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.